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Abstract
There have been several reports on the varying rates of progression among Alzheimer’s Disease (AD) patients; however,
there has been no quantitative study of the amount of heterogeneity in AD. Obtaining a reliable quantitative measure of AD
progression rates and their variances among the patients for each stage of AD is essential for evaluating results of any
clinical study. The Global Deterioration Scale (GDS) and Functional Assessment Staging procedure (FAST) characterize seven
stages in the course of AD from normal aging to severe dementia. Each GDS/FAST stage has a published mean duration, but
the variance is unknown. We use statistical analysis to reconstruct GDS/FAST stage durations in a cohort of 648 AD patients
with an average follow-up time of 4.78 years. Calculations for GDS/FAST stages 4–6 reveal that the standard deviations for
stage durations are comparable with their mean values, indicating the presence of large variations in the AD progression
among patients. Such amount of heterogeneity in the course of progression of AD is consistent with the existence of several
sub-groups of AD patients, which differ by their patterns of decline.
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Introduction
The temporal progression of Alzheimer’s Disease (AD) shows a
pattern of high variability, with patients transiting the stages of the
disease having time-courses ranging from months to decades [1,2].
While the biological correlates of this variability have been
investigated by many groups [2–19], the underlying reasons for
such variations remain largely uncertain. One of the challenges
posed by a high variability of a temporal disease course is the
difficulty in treatment efficiency assessments. For any current and
future progression-delaying drug, it is important to be able to
establish whether and by how much it delays the deterioration
caused by AD. To this end, it is necessary to have a reliable
quantification of the heterogeneity of the disease.
Global Deterioration Scale (GDS) was proposed in [20] and
allowsprofessionalsandcaregiverstochartthedeclineofpeoplewith
AD. While a number of scales exist, GDS is one of the most widely
used instruments to stage the course of AD. It measures cognitive,
behavioral and functional impairment of patients. There are a total
of 7 GDS stages (from stage 1 corresponding to no impairment to
stage 7 corresponding to the most severe AD). In particular, stage 4
(mild AD) is characterized by patients requiring assistance in
complex taskssuchashandling finances,planning a dinner party etc.
In GDS stage 5 (moderate AD) patients require assistance in
choosing proper attire. In stage 6 (moderately severe AD) patients
require assistance in dressing and bathing, and start experiencing
urinary and fecal incontinence. GDS has been shown to correlate
with both behavioral measures, and anatomic brain changes [20].
Functional Assessment Staging procedure (FAST) was proposed
in Ref. [21,22]. Based on GDS, this procedure describes a
continuum of 16 successive stages and substages from normality to
most severe dementia of the AD type. The FAST stages have been
enumerated to be concordant with the GDS stages from which
they were derived [23], although some differences between the two
scales have also been demonstrated [24]. One of the advantages of
GDS/FAST staging system is that it allows the assessment and
staging of AD in its entire range from normal aging to very severe,
end-stage, AD [25].
In the literature, the course of AD as characterized by GDS/
FAST staging system has been described in quantitative terms. In
particular, the stages are thought to follow in a sequential fashion
and are characterized by certain stage durations [26]. For
example, stage 4 is thought to last for 2 years, to be followed by
stage 5 whose duration is 1.5 years, which in turn is followed by
stage 6 (2.5 years).
While this quantification is a useful diagnostic tool, it reflects the
average course of the disease and provides no information about
possible heterogeneity of AD progression. At the same time,
quantifying the variance of GDS/FAST stage durations is essential,
as one needs to compare the delay gained by a treatment strategy
withthe amount of natural variationin stage durations, to be able to
judge whether there is significance to any improvements observed.
In this paper we investigate the heterogeneity of AD by studying the
distribution of GDS/FAST stage durations of AD patients. We ask:
how much variability is there in the course of AD, and how well do
the average values for GDS/FAST stage durations reflect the
disease course of individual patients?
Results
The estimates for the cumulative probability distributions of
GDS/FAST stage durations are presented in figure 1. We can see
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This is further illustrated in figure 2 where we show the mean values
of the GDS/FAST stage durations together with their standard
deviations. In both figures, the values pertaining to the GDS system
are plotted in black, and those for FAST staging are represented by
gray lines. We can see that for stages 4 and 5, the FAST stage mean
durations are slightly shorter than the GDS mean durations, and for
stage6,theFASTstagemeandurationislongerthanthatcalculated
for the GDS system. We can also see that for stages 4,5 and 6, the
estimated mean durations are somewhat longer than those given in
[27] (the values from [27] for each GDS/FAST stage are shown by
dashed horizontal lines). Despite this fact, we canseethat, consistent
with the literature, the GDS/FAST stage 5 is the shortest of the
three stages, followed by stages 4, and 6.
A striking observation can be made by looking at the calculated
values for the standard deviations of the stage durations. In
figure 2, the standard deviation values are represented by vertical
bars around the mean, and are also shown in brackets next to the
calculated means. Both for GDS and FAST staging systems, the
standard deviations are relatively large. For example, for the
shorter stages 4 and 5, the standard deviations are of the order of
the mean values for stage durations, and for the longer stage 6, the
standard deviations exceed 50% of the mean stage duration
values. Given such large standard deviations of stage length
durations, it is remarkable that the calculated mean values of
stages 4 and 5 are so close to the previously reported durations;
and for stage 6, the calculated means are definitely within a
standard deviation from the value in [27]. We further observe that
the differences between the GDS and FAST measurements are
also well within the standard deviation, so we cannot conclude that
the two systems yield different mean values [25].
Discussion
Analysis of a large longitudinal dataset has revealed a significant
degree of variation in the lengths of GDS/FAST stages 4–6 of AD.
In particular, the calculated standard deviations for GDS/FAST
stage durations turned out to have values similar to their mean
durations. This is an indication that the patterns of cognitive and
functional decline vary significantly from patient to patient.
The suggestion that AD is a genuinely heterogeneous disease, has
been proposed in the literature [28]. One paper [29] studies a 4-year
longitudinal dataset, and identifies four different subgroups of AD
patients which differ by the rate of their intellectual and functional
decline as well as other symptoms. Ref. [30] states that AD shows
heterogeneity in its clinical, anatomic, and physiologic characteris-
tics, and identifies several patient subtypes with respect to different
characteristics, including the time course of progression. In
particular, inhomogeneity is observed with respect to the rates of
ventricleenlargement, which are related to rates of cognitive decline.
InRef.[31],thepresenceofaphasiainADpatientsiscorrelatedwith
a more rapid course of the disease. This is done by performing
extensive testing of the patients, as well as interviewing reliable
informants, in the course of a 2.5 year-long follow-up. Ref. [2]
follows patients for 3 year, and discovers an association between
relatively severe frontal lobe involvement and a rapid clinical course
of AD, measured by using the dementia rating scale and estimating
the symptom duration time. A recent paper, Ref. [32], examines AD
data from a 15-year longitudinal study, and provides important
insights into the patterns of progression of AD. It identifies three
groups of patients based on their initial (pre-progression) rate. This
rate is estimated byusing the (normalized) Mini Mental Status Exam
(MMSE) score at base-line, divided by the symptoms’ duration. It is
found that the different groups remain separate in the course of the
follow-ups, which is consistent with our previous finding [33]. Most
relevant to our present study, it is found that the average rates of
decline for the three groups are different for three types of measures:
acognitivemeasure(Alzheimer’sdiseaseAssessmentScale-Cognitive
Subscale), a functional measure (Physical Self-Maintenance Scale),
and a global measure (Clinical Dementia Rating Scale Sum of
Boxes). Although no direct estimate of the variation has been
presented, these results clearly show that AD progression rates are
heterogeneous in many respects.
The patient data used here come from a longitudinal study
conveyed between 1983 and 2006. It is theoretically possible that
the large variation observed in the cohort of patients is a
Figure 1. The calculated cumulative probability distribution functions for GDS/FAST stage durations.
doi:10.1371/journal.pcbi.1002251.g001
Author Summary
In recent decades, our understanding of Alzheimer’s
disease (AD) has increased; however, some basic questions
still remain unresolved. One of them is: how homogeneous
is AD? Is the course of progression more or less the same
for most patients, or are there large variations? Our paper
studies a large cohort of AD patients which comes from a
23-year-long study, and performs a statistical analysis of
progression speed. We quantify the amount of spread in
GDS/FAST stage durations (a staging system widely used
by clinicians). We arrive at an astonishing conclusion that
the mean length of AD stages is comparable with their
standard deviation! This means that individual courses of
AD progression may differ very much from each other, and
from the textbook mean values. This has implications both
for clinical trials (how do we assess if a new drug is
effective, if the amount of natural spread is so large in
untreated patients?), and for our understanding of this
disease, which appears to be comprised of sub-diseases
with different patterns of decline.
Heterogeneity of Alzheimer’s Disease Progression
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course of AD progression. To explore this possibility, we have split
the cohort of patients into two subgroups based on their dates of
visit, and calculated the statistics of stage durations both for the
‘‘earlier’’ and the ‘‘later’’ parts of the cohort. We found that within
the subgroups, the variances of the stage durations were as large as
the ones reported here, and further, the mean values of stage
durations were not significantly different.
Note, however, that the analysis performed here was not
specificallydesignedtodiscernslighttrendsinthediseaseprogression
over the decades. We cannot perform such an analysis with the data
at hand because of the data scarcity issues (using smaller sub-groups
of patients necessarily jeopardizes the reliability of the statistics).
More data would be needed to catch the trends related to changes in
life-styleand othergenerational effects.Herewe could only conclude
that in both early and late halves of the cohort, the variances were
large, and stage durations were statistically not different.
Given a high variability of progression patterns, an important
question is finding variables that correlate with progression rates.
We have attempted to relate the rate of progression to demographic
factors, and determine if it correlates with age at baseline,sex,
education, or the age of onset of AD (which was back-calculated by
using the information on the estimated stage durations). No
significant correlations with these factors have been found, which
is consistent with several previous papers [2,13–19]. In the
literature, several factors have been proposed to be predictive of
the disease progression rate. The work of [34] highlights the
heterogeneity of AD, and shows that clusters of CSF biomarker
levels are related to patients’ cognitive profiles. In particular, it finds
that patients with extremely high CSF levels of tau and tau
phosphorylated at threonine 181 demonstrate a distinct cognitive
profile with more severe impairment of memory, mental speed, and
executive functions; importantly, these differences cannot be
explained by disease severity. Paper [35] finds that at the time of
diagnosis, a combination of high CSF tau without proportionally
elevated p-tau-181 is correlated with a faster rate of cognitive
decline in AD patients. In paper [36], the variability of AD is
explained in terms of specific types of EEG abnormalities. In paper
[37], heterogeneity of AD is related to genetic variation in patients,
such as that associated with cerebrospinal fluid phospho-tau levels.
It is plausible that a combination of many different factors is
responsible for a high variability of AD progression rates.
Our main finding is the large heterogeneity in the duration of
GDS/FAST stages in AD, which is consistent with the reports
Figure 2. The mean values and standard deviations calculated for GDS/FAST stages 4–6. The black bars represent GDS stages, and the
gray bars – FAST stages. The mean stage values reported in [27] are presented by dashed horizontal lines.
doi:10.1371/journal.pcbi.1002251.g002
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we use a very extensive (23-year long) longitudinal dataset for AD
patients, where there is a representation of patients at GDS/FAST
stages 4–7 of AD. We calculate the amount of variance in patients
explicitly, and demonstrate a large spread in values of GDS/FAST
stage values for stages 4, 5, and 6. There are several applications of
our results.
N Most immediately, having a standard deviation values (and not
just the mean values) for GDS/FAST stage durations is
important for those scientists and clinicians who use the GDS/
FAST staging system.
N Such large values of variance in GDS/FAST stage durations
caution against interpreting the GDS/FAST system as a
prognostic tool: the course of decline of individual patients can
be very different from the mean.
N Having the estimate on the GDS/FAST stage durations
calculated in such an extensive longitudinal dataset shows the
amount of heterogeneity in the course of progression of AD.
This is consistent with the existence of several sub-groups of
AD patients, which differ by their patterns of decline, see also
[33].
N The knowledge of stage durations together with their natural
variance is a necessary tool for the clinical trials. It allows to
make quantitative judgments about new drugs’ efficiency.
To conclude, we analyzed a longitudinal dataset to extract the
mean and the standard deviation for GDS/FAST stage durations
for stages 4–6 of AD. Applying similar methodology to larger
datasets with more frequent assessments will reveal more accurate
results.
Materials and Methods
In order to calculate the probability distribution of stage
durations in AD, we used a longitudinal dataset of AD patients,
which is an outcome of a longitudinal study performed between
the years 1983 and 2006 [33]. The following information is
contained in the dataset: the date of each patient’s visit to the
Medical Center, current GDS and FAST stage, and some
Figure 3. Some statistics of the dataset. (a) A histogram showing the number of records per patient. (b) A histogram showing patient inter-visit
times.
doi:10.1371/journal.pcbi.1002251.g003
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years of education). The total number of AD patients in the dataset
is 1321, of which 648 have repeated records (that is, they were
seen more than once). The latter group is the one we considered in
this study. The mean number of records per patient is 2.660.9;
the histogram of the number of records for different patients is
presented in figure 3(a). The patients’ age at the first visit to the
clinic is 73.168.7 years (see figure 3(b) for the age-distribution).
66% of the patients are female, and 34% male; the average length
of education received by the patients is 13.163.4 years.
Extracting accurate estimates for the standard deviations for
longitudinal datasets is complicated by the practical realities of
how the data is collected. First of all, we only know the current
stage at the times of assessments, but we have no information on
when each stage actually starts and the next one begins (in other
words, the data is left-and right- censored). Further complication
comes from the fact that the patients’ total observation time (time
from first to last visit) was 4.78 6 2.94 years, see the histogram of
figure 3(c). This means that many patients in the cohort were not
followed for the entire course of their disease. Table 1 shows a split
of all the patients into transition classes, that is, it counts the
number of patients first seen in stage i, and last seen in stage j. This
quantifies exactly how many patients contribute to the calculations
for different stages. It is obvious that the information coming from
each individual patient is not nearly sufficient to reconstruct all the
FAST/GDS stage durations. A method is required which would
allow to combine data from different patients to reconstruct the
stage duration distributions for the whole cohort (although the
information coming from individual patients is incremental).
Finally, another problem is illustrated in figure 3(d), where we
present the inter-visit time distribution, which shows how long the
patients waited before their next visit to the doctor. We can see
that: (1) the distribution has a strong peak around 2 years, and
then a weaker mode around 4 years, which tells us that the
sampling times are strongly biased (the reason for this shape of the
distribution is that the next appointment is usually recommended
after two years); and (2) the average inter-visit time, which is
3.0361.59, is comparable with the approximate average stage
duration for FAST stages 4–6, which makes this dataset very
‘‘coarse’’ and not ideally suited for extracting stage time variations.
Analysis of long, multistage disease processes has been
addressed in literature in many different context [38–40].
Statistical approaches to estimating the mean stage durations
from a set of AD patients medical records have centered on a
linear regression approach [26], where the mean duration of
FAST stages were determined, or the use of statistics such as the
Kaplan-Meier estimate [32,41] to determine the survival times of
patients. Unfortunately, the linear regression method does not lend
itself to calculating the variances of FAST stage durations (see Text
S1). Here we used the methodology developed by [42–44] to
approximate the probability distribution of stage durations.
We view the beginning and the end of each stage as censored
events. For each stage i, for each patient, we identify the latest
record when they were diagnosed with a stage prior to i (e.g. stage
i-1), and then the earliest record where they were diagnosed with
stage i or higher. These two time-points give us the interval of time
where stage i began, [XL,XR]. Similarly, the latest record in stage i
or lower, together with the earliest record at a stage higher than i,
give the time-interval where stage i ended, [ZL,ZR]. Some of the
right bounds are set to infinity for the lack of appropriate records.
We further make an assumption on the patients’ first visit, see Text
S1 and also [33]: for patients who come to the doctor’s office for
the first time, we assume that the date of the visit effectively
coincides with the onset of the current stage.
We used the iterative approach developed in [43] to
approximate the probability distribution function of stage
durations for stages 4, 5 and 6. We did not perform the analysis
for stage 3 because the number of records for GDS/FAST stages 3
and lower was very small in the database. For stage 7, we were not
able to extract meaningful information on the stage duration
because of the absence of data on patients’ death. The obtained
solutions were further checked against a non-parametric numerical
estimate of the cumulative distribution function obtained by a
straightforward counting method. The two methods are mathe-
matically different, but they revealed very similar results. Further
details of the methodology are given in Text S1.
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